BioCentury | Jan 10, 2020
Company News

Management tracks: COO, CMO depart as Solid restructures; plus Abeona, Millendo, Immuneering, Akouos, Kintai, Macrophage, Selexis, Prime

...chairman. Mendlein, an executive partner at Flagship Pioneering, succeeds Jim Gilbert at the Flagship company. Macrophage Pharma Ltd....
...at Medco Health Solutions Inc. Hongjiang Li, Staff Writer and Sandi Wong, Assistant Editor Akouos Inc. Kintai Therapeutics Inc. Macrophage Pharma Ltd. Millendo...
BioCentury | Oct 21, 2019
Emerging Company Profile

Verseau unveils tumor macrophage reprogramming strategy

...Pharmaceuticals Oy has Clevegen, which targets STAB1, in Phase I/II testing for solid tumors and Macrophage Pharma Ltd....
BioCentury | Sep 3, 2019
Company News

Management tracks: Tempus brings on former FDA chief of staff; plus Bayer, Genfit, Accent and more

...Shakti Narayan as CEO. He was CBO of Tango Therapeutics Inc. (Cambridge, Mass.). Immuno-oncology company Macrophage Pharma Ltd....
...plc (NASDAQ:NBRV). Jonathan Block, Associate Editor and Steve Usdin, Washington Editor Accent Therapeutics Inc. Akouos Inc. Bayer AG Dynacure S.A.S. Genfit S.A. Macrophage Pharma Ltd. Tempus...
BioCentury | Mar 14, 2019
Emerging Company Profile

Silverback: Taking on tumoral myeloid cells

...TLR8 agonists in the clinic for cancer. At least two others, Faron Pharmaceuticals Oy and Macrophage Pharma Ltd....
...Research (AACR), Philadelphia, Pa. Celgene Corp. (NASDAQ:CELG), Summit, N.J. Faron Pharmaceuticals Oy (LSE:FARN), Turku, Finland Macrophage Pharma Ltd....
BioCentury | Mar 8, 2019
Targets & Mechanisms

Flipping the switch in immuno-oncology

...efficacy in the first three patients treated in a Phase I/II trial in solid tumors. Macrophage Pharma Ltd....
...cells to express CARs or inducing a type 1 interferon response. Transcriptional switch Faron and Macrophage Pharma...
...Tregs decreased 10% from baseline. Faron plans to report dose-escalation data from MATINS in mid-2019. Macrophage Pharma’s...
BioCentury | Sep 1, 2017
Financial News

Macrophage raises L3M to close L12M series A

...On Aug. 23, immuno-oncology company Macrophage Pharma Ltd. (Windsor, U.K.) said it raised £3 million ($3.9 million) from...
...Novo Holdings A/S (Hellerup, Denmark) and Aglaia Biomedical Ventures also participated. Macrophage Pharma Ltd. , Windsor, U.K. Mary Romeo Macrophage Pharma Ltd....
BioCentury | May 25, 2017
Finance

Europe’s translational springtime

...2016 Cambridge, U.K. Cancer Research UK £25M ($33.2M) Targeting DNA damage repair pathways Cancer Preclinical Macrophage Pharma Ltd....
BioCentury | May 18, 2017
Emerging Company Profile

Spreading Carma

...BCIQ database, no companies have disclosed programs involving adoptive transfer of macrophages for any indication. Macrophage Pharma Ltd....
...Cancer Research, Philadelphia, Pa. Carma Therapeutics LLC, Philadelphia, Pa. GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K. Macrophage Pharma Ltd....
...Research (2017) Martz, L. “Eating cancer.” BioCentury Innovations (2017) Karen Tkach Tuzman, Senior Writer Carma Therapeutics LLC GlaxoSmithKline plc Macrophage Pharma Ltd. University...
BioCentury | Apr 13, 2017
Translation in Brief

Eating cancer

...therapy that uses chimeric antigen receptors (CARs) to induce the cells to phagocytose cancer cells. Macrophage Pharma Ltd....
BioCentury | Jan 20, 2017
Company News

Chroma, Macrophage deal

...macrophages. Chroma Therapeutics Ltd. , Abingdon, U.K. Macrophage Pharma Ltd. , Windsor, U.K. Business: Cancer Alicia Parker Chroma Therapeutics Ltd. Macrophage Pharma Ltd....
Items per page:
1 - 10 of 11
BioCentury | Jan 10, 2020
Company News

Management tracks: COO, CMO depart as Solid restructures; plus Abeona, Millendo, Immuneering, Akouos, Kintai, Macrophage, Selexis, Prime

...chairman. Mendlein, an executive partner at Flagship Pioneering, succeeds Jim Gilbert at the Flagship company. Macrophage Pharma Ltd....
...at Medco Health Solutions Inc. Hongjiang Li, Staff Writer and Sandi Wong, Assistant Editor Akouos Inc. Kintai Therapeutics Inc. Macrophage Pharma Ltd. Millendo...
BioCentury | Oct 21, 2019
Emerging Company Profile

Verseau unveils tumor macrophage reprogramming strategy

...Pharmaceuticals Oy has Clevegen, which targets STAB1, in Phase I/II testing for solid tumors and Macrophage Pharma Ltd....
BioCentury | Sep 3, 2019
Company News

Management tracks: Tempus brings on former FDA chief of staff; plus Bayer, Genfit, Accent and more

...Shakti Narayan as CEO. He was CBO of Tango Therapeutics Inc. (Cambridge, Mass.). Immuno-oncology company Macrophage Pharma Ltd....
...plc (NASDAQ:NBRV). Jonathan Block, Associate Editor and Steve Usdin, Washington Editor Accent Therapeutics Inc. Akouos Inc. Bayer AG Dynacure S.A.S. Genfit S.A. Macrophage Pharma Ltd. Tempus...
BioCentury | Mar 14, 2019
Emerging Company Profile

Silverback: Taking on tumoral myeloid cells

...TLR8 agonists in the clinic for cancer. At least two others, Faron Pharmaceuticals Oy and Macrophage Pharma Ltd....
...Research (AACR), Philadelphia, Pa. Celgene Corp. (NASDAQ:CELG), Summit, N.J. Faron Pharmaceuticals Oy (LSE:FARN), Turku, Finland Macrophage Pharma Ltd....
BioCentury | Mar 8, 2019
Targets & Mechanisms

Flipping the switch in immuno-oncology

...efficacy in the first three patients treated in a Phase I/II trial in solid tumors. Macrophage Pharma Ltd....
...cells to express CARs or inducing a type 1 interferon response. Transcriptional switch Faron and Macrophage Pharma...
...Tregs decreased 10% from baseline. Faron plans to report dose-escalation data from MATINS in mid-2019. Macrophage Pharma’s...
BioCentury | Sep 1, 2017
Financial News

Macrophage raises L3M to close L12M series A

...On Aug. 23, immuno-oncology company Macrophage Pharma Ltd. (Windsor, U.K.) said it raised £3 million ($3.9 million) from...
...Novo Holdings A/S (Hellerup, Denmark) and Aglaia Biomedical Ventures also participated. Macrophage Pharma Ltd. , Windsor, U.K. Mary Romeo Macrophage Pharma Ltd....
BioCentury | May 25, 2017
Finance

Europe’s translational springtime

...2016 Cambridge, U.K. Cancer Research UK £25M ($33.2M) Targeting DNA damage repair pathways Cancer Preclinical Macrophage Pharma Ltd....
BioCentury | May 18, 2017
Emerging Company Profile

Spreading Carma

...BCIQ database, no companies have disclosed programs involving adoptive transfer of macrophages for any indication. Macrophage Pharma Ltd....
...Cancer Research, Philadelphia, Pa. Carma Therapeutics LLC, Philadelphia, Pa. GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K. Macrophage Pharma Ltd....
...Research (2017) Martz, L. “Eating cancer.” BioCentury Innovations (2017) Karen Tkach Tuzman, Senior Writer Carma Therapeutics LLC GlaxoSmithKline plc Macrophage Pharma Ltd. University...
BioCentury | Apr 13, 2017
Translation in Brief

Eating cancer

...therapy that uses chimeric antigen receptors (CARs) to induce the cells to phagocytose cancer cells. Macrophage Pharma Ltd....
BioCentury | Jan 20, 2017
Company News

Chroma, Macrophage deal

...macrophages. Chroma Therapeutics Ltd. , Abingdon, U.K. Macrophage Pharma Ltd. , Windsor, U.K. Business: Cancer Alicia Parker Chroma Therapeutics Ltd. Macrophage Pharma Ltd....
Items per page:
1 - 10 of 11